OTIC GEL FORMULATIONS FOR TREATING OTITIS MEDIA
Disclosed herein are methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
1 . A method of treating otitis media in a subject having a tympanostomy tube placed in at least one ear of the subject, wherein the tympanostomy tube comprises an exterior side facing external ear canal, an interior side facing middle ear, and tubular wall extending between the exterior and interior sides, the method comprising administering on the external side of the tympanostomy tube an otic composition comprising an auris-acceptable gel and a multiparticulate antimicrobial agent.
2 . The method of claim 1 , wherein the otitis media is acute otitis media.
3 . The method of claim 1 , wherein the otitis media is otitis media with effusion.
4 . The method of claim 1 , wherein the otitis media is acute otitis media with tympanostomy tube (AOMT).
5 . The method of claim 1 , wherein the auris-acceptable gel is a thermoreversible gel.
6 . The method of claim 1 , wherein the antimicrobial agent is ciprofloxacin.
7 . The method of claim 1 , wherein the otic composition comprises about 6.0% by weight of micronized ciprofloxacin and 15-17% by weight of poloxamer 407.
8 . The method of claim 1 , comprising suctioning the ear prior to administering the otic composition.
9 . The method of claim 1 , comprising administering the otic composition with a catheter, cannula, or needle.
10 . The method of claim 9 , wherein the catheter, cannula, or needle has a blunt tip.
11 . The method of claim 9 , wherein the catheter, cannula or needle does not pierce the tympanic membrane of the subject.
12 . The method of claim 9 , wherein the catheter, cannula or needle does not insert into the tubular wall of the tympanostomy tube.
13 . The method of claim 9 , wherein the catheter, cannula or needle does not insert through the tubular wall of the tympanostomy tube.
14 . The method of claim 1 , comprising administering a volume of about 0.1 mL to about 0.4 mL of the aqueous composition.
15 . The method of claim 1 , comprising administering a volume of about 0.1 mL to about 0.2 mL of the aqueous composition.
16 . The method of claim 1 , wherein the composition comprises from about 6 mg to about 24 mg by weight of micronized ciprofloxacin.
17 . The method of claim 1 , wherein the composition comprises from about 10 mg to about 15 mg by weight of micronized ciprofloxacin.
18 . The method of claim 1 , wherein the composition comprises about 12 mg by weight of micronized ciprofloxacin.
19 . The method of claim 1 , wherein the composition is free of butylated hydroxytoluene (BHT).
20 . The method of claim 1 , wherein the composition is preservative-free.
21 . The method of claim 1 , wherein the composition further comprises tromethamine.
22 . The method of claim 1 , wherein the composition has a pH of about 7.0 to about 8.0.
23 . The method of claim 1 , wherein the otic disease or condition is associated with a bacterial infection.
24 . The method of claim 23 , wherein the bacterial infection is associated with Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus rettgeri, Proteus vulgaris, Proteus morgani, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus faecalis, Alcaligenes faecalis, Klebsiella aerogenes, Klebsiella pneumonia, Haemophilus influenzae, Moraxella catarrhalis , or a combination thereof.